Ebola virus vaccine: benefit and risks of adenovirus-based vectors.

  title={Ebola virus vaccine: benefit and risks of adenovirus-based vectors.},
  author={Franck J D Mennechet and Thi Thu Phuong Tran and Karsten Eichholz and Philippe Van de Perre and Eric J Kremer},
  journal={Expert review of vaccines},
  volume={14 11},
In 2014, an outbreak of Ebola virus spread rapidly in West Africa. The epidemic killed more than 10,000 people and resulted in transmissions outside the endemic countries. WHO hopes for effective vaccines by the end of 2015. Numerous vaccine candidates have been proposed, and several are currently being evaluated in humans. Among the vaccine candidates are vectors derived from adenovirus (Ad). Despite previous encouraging preclinical and Phase I/II trials, Ad vectors used in three Phase II… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS

From This Paper

Topics from this paper.

Similar Papers

Loading similar papers…